Wells Fargo & Company MN Sells 145,067 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Wells Fargo & Company MN lowered its position in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 48.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 156,748 shares of the company's stock after selling 145,067 shares during the period. Wells Fargo & Company MN owned 0.23% of COMPASS Pathways worth $593,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of COMPASS Pathways during the fourth quarter worth $41,000. Wealthfront Advisers LLC bought a new position in shares of COMPASS Pathways during the fourth quarter worth approximately $43,000. Flagship Harbor Advisors LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter valued at approximately $43,000. Conservest Capital Advisors Inc. grew its position in COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after buying an additional 3,000 shares in the last quarter. Finally, Simplify Asset Management Inc. bought a new position in COMPASS Pathways during the 4th quarter worth $54,000. 46.19% of the stock is owned by institutional investors and hedge funds.

COMPASS Pathways Trading Down 0.8 %

Shares of NASDAQ:CMPS traded down $0.03 during mid-day trading on Thursday, hitting $3.71. The company had a trading volume of 132,145 shares, compared to its average volume of 798,714. The firm has a fifty day moving average price of $3.34 and a 200 day moving average price of $4.07. COMPASS Pathways plc has a one year low of $2.49 and a one year high of $9.63. The company has a market capitalization of $343.82 million, a PE ratio of -1.69 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.03. As a group, research analysts forecast that COMPASS Pathways plc will post -2.33 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on CMPS shares. HC Wainwright restated a "buy" rating and set a $45.00 price objective on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Stifel Nicolaus initiated coverage on COMPASS Pathways in a research report on Thursday, February 27th. They set a "buy" rating and a $11.00 price objective for the company. Canaccord Genuity Group lowered their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, February 28th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a report on Friday, March 28th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways currently has an average rating of "Buy" and a consensus price target of $20.20.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.